Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer as the drugmakers jostled for advantage in the highly lucrative weight-loss drug market.

Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring almost 4% after its earnings call on Thursday.

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s unsolicited proposal to acquire Metsera, renewed legal action against Tylenol’s manufacturer following statements from Robert F. Kennedy Jr., and AbbVie’s stronger 2025 profit outlook driven by immunology demand.

Novo Nordisk cuts over 800 jobs in Plainsboro, part of a global restructuring under the new CEO, reflecting a troubling trend of layoffs across New Jersey's healthcare and hospitality sectors.

Novo Nordisk layoffs: Denmark-based pharmaceuticals major, Novo Nordisk's Chief Executive Officer (CEO) Mike Doustdar, on Friday, 31 October 2025, said that the company has notified its employees who have been impacted by the job cuts in the majority of locations amid the company-wide restructuring drive.

Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be Worried? While that could be an issue for Novo Nordisk, it should find a way to navigate ongoing price negotiations.